← All trials
NCT05338970
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2022
- Primary completion
- Aug 30, 2024
- Completion date
- Aug 4, 2026
- First posted
- Apr 21, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 560
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daiichi SankyoLead sponsor
- Daiichi SankyoStudy chair
- Daiichi SankyoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.